The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Challenges in lung cancer multidisciplinary collaboration experienced by specialists in four countries.
 
Suzanne Murray
Employment - AXDEV
Stock and Other Ownership Interests - AXDEV
Research Funding - AXDEV
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape
 
Christian Grohé
No Relationships to Disclose
 
Kazuhiko Nakagawa
Honoraria - 3H Clinical Trial; Abbvie; Amgen; Amgen; AstraZeneca Japan; Bayer Yakuhin; Bristol-Myers Squibb; CareNet; Chugai Pharma; Kyorin; Kyowa Kirin Co., Ltd.; Lilly; Medical Mobile Communications; Medical Review Co., Ltd.; Merck; MSD K.K; Nikkei Business Publications, Inc; Nippon Boehringer Ingelheim; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Roche; Taiho Pharmaceutical; Takeda; YODOSHA
Consulting or Advisory Role - Kyorin; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Covance (Inst); Covance (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS International (Inst); GlaxoSmithKline K.K. (Inst); IQvia (Inst); Japan Clinical Research Operations (Inst); Kissei Pharmaceutical (Inst); Lilly (Inst); Medical Reserch Support (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD K.K (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); PAREXEL International Corp. (Inst); Pfizer (Inst); Pfizer (Inst); PPD-SNBL (Inst); PRA HEALTHSCIENCES (Inst); Sanofi (Inst); SymBio Pharmaceuticals (Inst); Syneos Health (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Sacha Zahabi
Employment - AXDEV
Research Funding - AXDEV
 
Anthony Sireci
Employment - Loxo
Stock and Other Ownership Interests - Lilly
Research Funding - UnitedHealthcare (Inst)
 
Steven I. Sherman
Honoraria - Eisai
Consulting or Advisory Role - Exelixis; Lilly; Loxo
Research Funding - Exelixis (Inst)
 
Elizabeth Kelly
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Patrice Lazure
Employment - Axdev
Research Funding - Axdev